Stay updated with breaking news from Revised Upper Limb Module. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it
Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events decreased over the same periodPart 2 of SUNFISH... | March 16, 2022
New data demonstrates the long-term safety and efficacy of Evrysdi® (risdiplam) in a broad population of people with spinal muscular atrophy.
Investegate announcements from F. Hoffmann-La Roche Ltd, New data for Roche’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA)
Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events decreased over the same periodPart 2 of SUNFISH showed Evrysdi